BA
NMTC icon

Bard Associates’s NeuroOne Medical Technologies NMTC Stock Holding History

Bard Associates’s Portfolio NMTC Stock Details NMTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$929K Sell
305,428
-1,322
-0.4% -$5.4K 0.21% 77
2026
Q1 		$1.43M Sell
306,750
-1,083
-0.4% -$5.2K 0.36% 61
2025
Q4 		$1.4M Sell
307,833
-667
-0.2% -$3.04K 0.36% 68
2025
Q3 		$1.64M Sell
308,500
-600
-0.2% -$2.94K 0.44% 67
2025
Q2 		$1.26M Buy
+309,100
New +$1.14M 0.4% 80

Other funds holding NMTC

BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PCM
Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
EIM
Essex Investment Management Boston, Massachusetts $763M AUM 108.51% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bard Associates's NMTC Position: Q2 2026 in Review

Bard Associates reduced its NeuroOne Medical Technologies (NMTC) stake by 0.43% in Q2 2026, selling an estimated $5.4K and leaving 305,428 shares worth $929K. The position accounts for 0.21% of the portfolio, ranked #77.

Bard Associates first reported a position in NMTC in Q2 2025 and has held it in 5 quarters since. The position peaked at $1.64M in Q3 2025. 27 funds tracked by Wall St. Rank hold NMTC as of Q2 2026.

  • Bard Associates held 305,428 shares of NeuroOne Medical Technologies worth $929K as of Q2 2026.
  • Bard Associates sold 1,322 NeuroOne Medical Technologies shares in Q2 2026, an estimated $5.4K.
  • NeuroOne Medical Technologies made up 0.21% of Bard Associates's portfolio in Q2 2026, its #77 holding.
  • Bard Associates first reported a position in NeuroOne Medical Technologies in Q2 2025 and has held it in 5 quarters since.
  • Bard Associates's NeuroOne Medical Technologies position peaked at $1.64M in Q3 2025.
  • 27 funds tracked by Wall St. Rank held NeuroOne Medical Technologies as of Q2 2026.

Based on Bard Associates's 13F filing for Q2 2026, filed 12 Aug 2026.